| Literature DB >> 28648284 |
Jittiporn Chaisaingmongkol1, Anuradha Budhu2, Hien Dang2, Siritida Rabibhadana3, Benjarath Pupacdi3, So Mee Kwon2, Marshonna Forgues2, Yotsawat Pomyen4, Vajarabhongsa Bhudhisawasdi5, Nirush Lertprasertsuke6, Anon Chotirosniramit6, Chawalit Pairojkul5, Chirayu U Auewarakul7, Thaniya Sricharunrat8, Kannika Phornphutkul9, Suleeporn Sangrajrang10, Maggie Cam11, Ping He12, Stephen M Hewitt13, Kris Ylaya13, Xiaolin Wu14, Jesper B Andersen15, Snorri S Thorgeirsson2, Joshua J Waterfall16, Yuelin J Zhu16, Jennifer Walling16, Holly S Stevenson16, Daniel Edelman16, Paul S Meltzer16, Christopher A Loffredo17, Natsuko Hama18, Tatsuhiro Shibata19, Robert H Wiltrout20, Curtis C Harris2, Chulabhorn Mahidol21, Mathuros Ruchirawat22, Xin W Wang23.
Abstract
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We identified common molecular subtypes linked to similar prognosis among 199 Thai ICC and HCC patients through systems integration of genomics, transcriptomics, and metabolomics. While ICC and HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype is linked to obesity, T cell infiltration, and bile acid metabolism. These molecular subtypes are found in 582 Asian, but less so in 265 Caucasian patients. Thus, Asian ICC and HCC, while clinically treated as separate entities, share common molecular subtypes with similar actionable drivers to improve precision therapy. Published by Elsevier Inc.Entities:
Keywords: TIGER-LC; cancer driver; cancer genomics; hepatocellular carcinoma; integrated genomics; intrahepatic cholangiocarcinoma; liver cancer; metabolomics; molecular subtypes; transcriptomics
Mesh：
Year: 2017 PMID： 28648284 PMCID： PMC5524207 DOI： 10.1016/j.ccell.2017.05.009
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743